Added to YB: 2026-09-14
Pitch date: 2026-09-11
ANNX [bullish]
Annexon, Inc.
Author Info
No bio for this author
Company Info
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Market Cap
$828.5M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.18
P/E
-3.88
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 3 Session 3 - Annexon, Inc.
ANNX (quick overview): Annexon at $4.10 offers an attractive but binary catalyst sequence: GBS is the nearer-term commercial opportunity, supported by approximately 90% week-one response in Phase 3, while geographic atrophy could materially change the valuation. A Q4 2026 DMC review is pivotal; management has discussed unmasked data only indirectly, so investors still need the actual month-15 outcome.
Read full article (2 min)